At a glance
- Retinalamin is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 25 publications mentioning it, including 3 randomized controlled trials and 4 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA's adverse event system (FAERS) holds 2 reports mentioning it; 1 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- [Neuroprotective therapy in advanced primary open-angle glaucoma].
- [Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy].
- [Objective functional monitoring of retinoprotective treatment in diabetic retinopathy].
- [Investigation of ligand-receptor interaction and biodistribution of a drug containing cattle retinal polypeptides in various administration routes].
- [Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas].
- [Effect of retinal protective therapy on optical coherence tomography angiography (pilot study)].
- [The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional tests].
- [Peptide bioregulators: delivery and efficacy].
- [Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy].
- [Structural and functional changes in the retinal layers in patients with primary glaucoma and possible means of retinoprotection].
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 2
- Serious
- 1
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.